Zydus Cadila can launch ulcer drug in US, patent litigation settled

The patent litigation relating to Allergan's Delzicol (mesalamine) has been settled, Zydus Cadila said in a statement. Representational Image. Image Source: Official Website

Drug firm Zydus Cadila on Saturday said the patent litigation relating to Allergan's Delzicol, used to treat ulcerative colitis, has been settled.

The patent litigation relating to Allergan's Delzicol (mesalamine) has been settled, Zydus Cadila said in a statement.

"As a result of the settlement, and if approved by Food and Drug Administration (FDA), its US subsidiary, Zydus Pharmaceuticals (USA) Inc, will be able to market its generic version of Delzicol in the US beginning on March 1, 2020, or earlier under certain circumstances," it added.

On Friday, the stock of Cadila Healthcare closed down 1.09% or Rs 4.35 at Rs 395.25 on the BSE.

See LIVE stock updates of Cadila Healthcare here-